Phase 4
Completed N=20
Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population
Source: ClinicalTrials.gov NCT00696488 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Mar 2017
Primary outcomePrimary: Adherence to Carac® in Subjects With Moderate to Severe Actinic Keratosis. — 86 percentage of prescribed doses
◆ Published Evidence
Established
41citations · ~2 / year
Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses.
Summary
The purpose of this research study is to measure adherence to the study drug (Carac) for the treatment of actinic keratoses.
Linked Publications
-
Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Adherence to Carac® in Subjects With Moderate to Severe Actinic Keratosis. |
86 | — |
Eligibility Criteria
Inclusion Criteria
- Any male or female 50 years of age or older with moderate to severe actinic keratoses of the face and anterior scalp diagnosed by a dermatologist will be eligible for participation.
Exclusion Criteria
- Age less than 50.
- Known allergy or sensitivity to topical Carac® in the subject.
- Inability to complete all study-related visits.
- Introduction of any other prescription medication, topical or systemic, for actinic keratosis while participating in the study.
- Subjects should not receive surgical or cryotherapy while participating in the study.
- Pregnant women, women who are breast feeding, or women of child bearing potential who are not practicing two acceptable methods of birth control
Data sourced from ClinicalTrials.gov (NCT00696488) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.